Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis

Vaccine

Volumn 30, Issue 5, 2012, Pages 936-940

  Dell'Era, Laura ^a   Corona, Fabrizia ^a   Daleno, Cristina ^a   Scala, Alessia ^a   Principi, Nicola ^a   Esposito, Susanna ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Adjuvants; Children; Influenza; Influenza vaccine; Juvenile idiopathic arthritis; MF59

Indexed keywords

BLOOD GROUP B ANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLUENZA VACCINE; INFLUENZA VIRUS ANTIBODY; MIFAMURTIDE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ARTICLE; CHILD; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; EATING HABIT; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALAISE; MALE; PRIORITY JOURNAL; RHINITIS; SCHOOL CHILD; SEROCONVERSION; SIDE EFFECT; SOMNOLENCE; VACCINATION; VIRUS STRAIN; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ANTIBODIES, VIRAL; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; ITALY; MALE; POLYSORBATES; SQUALENE;

EID: 84855427107     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.083     Document Type: Article

References (32)

1. Dell'Era L., Esposito S., Corona F., Principi N. Vaccination of children and adolescents with rheumatic diseases. Rheumatology 2011, 50:1358-1365.
2. Esposito S., Principi N. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr Opin Infect Dis 2009, 22:244-249.
3. Centers for Disease Control and Prevention (CDC) Prevention and control of influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010, 59(RR-8):1-68.
4. Davies K., Woo P. Immunization in rheumatic diseases of childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence. Rheumatology 2002, 41:937-941.
5. Gluck T., Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis 2008, 46:1459-1465.
6. Conti F., Rezai S., Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 2008, 8:124-128.
7. Kaine J.L., Kivitz A.J., Birbara C., Luo A.Y. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007, 34:272-279.
8. Kapetanovic M.C., Saxne T., Nilsson J.A., Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis. Rheumatology 2007, 46:608-611.
9. Gelinck L.B., van der Bijl A.E., Beyer W.E., Visser L.G., Huizinga T.W., van Hogezand R.A., et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008, 67:713-716.
10. van Assen S., Holvast A., Benne C.A., Posthumus M.D., van Leeuwen M.A., Voskuyl A.E., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62:75-81.
11. Malleson P.N., Tekano J.L., Scheifele D.W., Weber J.M. Influenza immunization in children with chronic arthritis: a prospective study. J Rheumatol 1993, 20:1769-1773.
12. Olson N.Y., Lindsley C.B., Page-Goertz S. Influenza immunization in children with chronic arthritis. J Rheumatol 1994, 21:1581.
13. Kanakoudi-Tsakalidou F., Trachana M., Pratsidou-Gertsi P., Tsitsami E., Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol 2001, 19:589-594.
14. Ogimi C., Tanaka R., Saitoh A., Oh-ishi T. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J 2011, 30:208-211.
15. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31:390-392.
16. Ansaldi F., Bacilieri S., Durando P., Sticchi L., Valle L., Montomoli E., et al. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008, 26:1525-1529.
17. Setti M., Fenoglio D., Ansaldi F., Filaci G., Bacilieri S., Sticchi L., et al. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009, 27:3367-3372.
18. Tanzi E., Esposito S., Bojanin J., Amendola A., Trabattoni D., Pariani E., et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006, 78:440-445.
19. European Agency for the Evaluation of Medicinal Products (EMEA) - Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96). London, March 12, 1997.
20. Kanra G., Marchisio P., Feiterna-Sperling C., Gaedicke G., Lazar H., Durrer P., et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004, 23:300-306.
21. Durando P., Icardi G., Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010, 10:639-651.
22. Esposito S., Pugni L., Daleno C., Ronchi A., Valzano A., Serra D., et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics 2011, 127:e1161-e1168.
23. Principi N., Esposito S., Marchisio P. Present and future of influenza prevention in pediatrics. Expert Opin Biol Ther 2011, 11:641-653.
24. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., O'Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28:563-571.
25. Vesikari T., Groth N., Karvonen A., Borkowski A., Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009, 27:6291-6295.
26. Esposito S., D'Angelo E., Daleno C., Peia F., Scala A., Serra D., et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major. Vaccine 2010, 28:7825-7828.
27. Esposito S., Meregalli E., Daleno C., Ghio L., Tagliabue C., Valzano A., et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol Dial Transplant 2011, 26:2018-2024.
28. Esposito S., Selicorni A., Daleno C., Valzano A., Cerutti M., Galeone C., et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome. Hum Vaccin 2011, 7:613-617.
29. Esposito S., Principi N. Different influenza vaccine formulations and adjuvants for childhood influenza vaccination. Vaccine 2011, [Epub August 3].
30. Fomin I., Caspi D., Levy V., Varsano N., Shalev Y., Paran D., et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers. Ann Rheuma Dis 2006, 65:191-194.
31. Salemi S., Picchianti-Diamanti A., Germano V., Donatelli I., Di Martino A., Facchini M., et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFα blockers: safety and immunogenicity. Clin Immunol 2010, 134:113-120.
32. Lu Y., Jacobson D.L., Ashworth L.A., Grand R.J., Meyer A.L., McNeal M.M., et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009, 104:444-453.